Renal metastasis of osteosarcoma is a rare entity, with paucity of reported cases in the literature. We report a case of a 20-year-old gentleman who was diagnosed with right distal femur osteosarcoma, complicated with multiple pulmonary recurrences. At two-year-and-a-half interval post-treatment completion, the patient developed right flank pain and frank haematuria. Contrasted abdominal computed tomography revealed a right renal mass with calcification and perinephric haematoma. A right radical nephrectomy was undertaken and histopathological examination showed metastatic condroblastic osteosarcoma. A literature review on renal metastasis secondary to osteosarcoma was performed and we present a report and discussion of these cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399285 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2022.102174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal cell carcinoma metastasis to the thyroid gland: a case report.
J Med Case Rep
December 2024
Laboratory of Pathology Pathology, "CSD Health Care", Kiev, Ukraine.
Background: In this article, we report a case of renal cell carcinoma metastasis to the thyroid gland. Occult lesions of the thyroid were treated with a thyroidectomy. The case history presented below describes the patient's pathway and subsequent results.
View Article and Find Full Text PDFIntegrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis.
Biol Direct
December 2024
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 Qingchun Road, Hangzhou, 310016, China.
Background: Precision oncology's implementation in clinical practice faces significant constraints due to the inadequacies in tools for detailed patient stratification and personalized treatment methodologies. Dysregulated tryptophan metabolism has emerged as a crucial factor in tumor progression, encompassing immune suppression, proliferation, metastasis, and metabolic reprogramming. However, its precise role in clear cell renal cell carcinoma (ccRCC) remains unclear, and predictive models or signatures based on tryptophan metabolism are conspicuously lacking.
View Article and Find Full Text PDFSurgery for patients with endometrioid-type endometrial cancer: is lymphadenectomy above the inferior mesenteric artery necessary?
World J Surg Oncol
December 2024
Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Objective: The primary objective of this study was to identify the risk of metastasis to lymph nodes above the inferior mesenteric artery (IMA) in endometrioid-type endometrial cancer (EC) and the factors that influence metastasis.
Methods: The study included patients who had been operated on for endometrioid-type EC in three gynecological oncology centers between 2007 and 2023. The supramesenteric lymph node (SM-LN) is the region between the left renal vein and the IMA, whereas the inframesenteric lymph node (IM-LN) is the region between the IMA and the aortic bifurcation, as determined by the level of the IMA.
Metastatic risk in clear cell renal cell carcinoma: a tool incorporating sex, size, and grade.
BJU Int
December 2024
Department of Urology, Zealand University Hospital, Roskilde, Denmark.
Objective: To identify predictors of metastases, estimate the proportion of metastatic clear cell renal cell carcinoma (ccRCC) cases according to these predictors, and subsequently create a risk table showing the absolute difference in metastasis proportion for each 10 mm increase in tumour size.
Patients And Methods: Patients diagnosed with histopathological confirmed ccRCC in 2010-2018 in Denmark identified in the nationwide Danish Multidisciplinary Renal Cancer Group (DaRenCa) Study-3. Association between diagnostic variables and metastases were assessed with logistic regression analyses.
Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access.
J Natl Cancer Inst
December 2024
University of Washington, Seattle, 98195, WA, USA.
Background: Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our objective was to evaluate contemporary trends in CECs among NCI-sponsored gynecologic cancer clinical trials and protocol adherence to broadened eligibility criteria guidelines as an assessment of equitable enrollment access.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!